Table 4.
Association between BRAF Mutations and Clinicopathological Characteristics
| Variables | BRAF V600E mutations | All BRAF mutations* | ||||
|---|---|---|---|---|---|---|
| Positive (%) (n=15) | Negative (%) (n=29) | P value | Positive (%) (n=19) | Negative (%) (n=25) | P value | |
| Gender | ||||||
| Female | 12 (80) | 24 (82.8) | 0.562 | 16 (84.2) | 20 (80) | 0.519 |
| Male | 3 (20) | 5 (17.2) | 3 (15.8) | 5 (20) | ||
| Age years | ||||||
| ≤45 years | 8 (53.3) | 14 (48.3) | 0.5 | 8 (42.1) | 14 (56) | 0.272 |
| >45 years | 7 (46.7) | 15 (51.7) | 11 (57.9) | 11 (44) | ||
| Type of thyroid cancer | ||||||
| Papillary carcinoma | 12 (80) | 14 (48.3) | 0.274 | 14 (73.7) | 12 (48) | 0.126 |
| Papillary carcinoma | 3 (20) | 6 (20.7) | 4 (21.1) | 5 (20) | ||
| Follicular variant | ||||||
| Follicular carcinoma | - | 4 (13.8) | - | 4 (16) | ||
| Medullary carcinoma | - | 3 (10.3) | - | 3 (12) | ||
| Anaplastic carcinoma | - | 1 (3.4) | 1 (5.2) | - | ||
| Poorly differentiated | - | 1 (3.4) | - | 1 (4) | ||
| Type of thyroid cancer | ||||||
| Papillary carcinoma | 15 (100) | 20 (69) | 0.014 | 18 (94.7) | 17 (68) | 0.032 |
| Others types of carcinoma | - | 9 (31) | 1 (5.2) | 8 (32) | ||
| Size, cm | ||||||
| ≤2 | 6 (40) | 8 (27.6) | 0.307 | 8 (42.1) | 6 (24) | 0.171 |
| >2 | 9 (60) | 21 (72.4) | 11 (57.9) | 19 (76) | ||
| Surgery | ||||||
| Left lobe | 2 (13.3) | 8 (27.6) | 0.504 | 3 (15.8) | 7 (28) | 0.606 |
| Right lobe | 6 (40) | 8 (27.6) | 7 (36.8) | 7 (28) | ||
| Total thyroid | 7 (46.7) | 13 (44.8) | 9 (47.4) | 11 (44) | ||
| Clinical Stage | ||||||
| I | 11 (73.3) | 17 (58.6) | 0.612 | 13 (68.4) | 15 (60) | 0.539 |
| II | 2 (13.3) | 3 (10.3) | 2 (10.5) | 3 (12) | ||
| III | 2 (13.3) | 8 (27.6) | 3 (15.8) | 7 (28) | ||
| IV | - | 1 (3.4) | 1 (5.3) | - | ||
| Lymph node involvement | ||||||
| N0 | 12 (80) | 25 (86.2) | 0.448 | 16 (84.2) | 21 (84) | 0.657 |
| N1 | 3 (20) | 4 (13.8) | 3 (15.8) | 4 (16) | ||
*V600E and non V600E mutations